

Haematologica  
HAEMATOL/2018/195032  
Version 3

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Panagiotis Baliakas, Theodoros Moysiadis, Anastasia Hadzidimitriou, Aliko Xochelli, Sabine Jeromin, Andreas Agathangelidis, Mattias Mattsson, Lesley-Ann Sutton, Eva Minga, Lydia Scarfò, Davide Rossi, Zadi Davis, Neus Villamor, Helen Parker, Jana Kotaskova, Evangelia Stalika, Karla Plevova, Larry Mansouri, Diego Cortese, Alba Navarro, Julio Delgado, Marta Larrayoz, Emma Young, Achilles Anagnostopoulos, Karin E Smedby, Gunnar Juliusson, Oonagh Sheehy, Mark Catherwood, Jonathan C Strefford, Niki Stavroyianni, Chrysoula Belessi, Sarka Pospisilova, David Oscier, Gianluca Gaidano, Elias Campo, Claudia Haferlach, Paolo Ghia, Richard Rosenquist, and Kostas Stamatopoulos

Disclosures: KS and PG received research support from Janssen Pharmaceuticals and Gilead Sciences. KS, PG and AH received research support from Novartis SA, Abbvie and Roche Hellas. The other co-authors declare no competing financial interests in relation to the present study.

Contributions: P.B. and T.M. designed the study, performed research and wrote the paper. A.H., A.X., S.B., A.A., M.M., L.S., E.M., L.S., D.R., Z.D. N.V., H.P., J.K., E.S., K.P., L.M., D.C., A.N., J.D., M.L., E.Y., A.A., K.S., G.J., O.S, M.K., J.S., N.S., C.B, S.P., D.O., G.G., E.C., C.H., P.G., and R.R provided data and performed research. K.S. designed the study and wrote the paper which was approved by all the authors.